HIP
FPRX

Hatteras Investment Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Hatteras Investment Partners’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,690
Closed -$319K – 113
2015
Q4 		$319K Buy
+7,690
New +$258K 0.42% 67

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Hatteras Investment Partners's FPRX Position: Q1 2016 in Review

Hatteras Investment Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2016, closing a stake of 7,690 shares — an estimated $319K sold.

Hatteras Investment Partners first reported a position in FPRX in Q4 2015 and held it in 1 quarter. The position peaked at $319K in Q4 2015. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

  • Hatteras Investment Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Hatteras Investment Partners sold 7,690 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $319K.
  • Hatteras Investment Partners first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Five Prime Therapeutics, Inc. position peaked at $319K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Hatteras Investment Partners's 13F filing for Q1 2016, filed 16 May 2016.